Go to the profile of NeuroBo Pharmaceuaticals

NeuroBo Pharmaceuaticals

 

About NeuroBo Pharmaceuaticals

NeuroBo Pharmaceuticals is addressing unmet needs in patients with Painful Diabetic Neuropathy (PDN) and Alzheimer’s disease. Their first product candidate, NB-01, is targeting neuropathic pain with a first indication in PDN. Phase 3 studies are planned and powered for efficacy and safety. Diabetes and cancer are amongst the leading causes of neuropathic pain. PDN affects 8.4M people worldwide representing global drug sales of $3.05B (2018, GlobalData) Current treatments show limited reduction of pain in half of patients

Therapeutic Areas

Neuroscience

Technologies

Other

Company Type

Biotechnology – R&D services

State of Ownership

Private

Sponsorship Group

Networker

Topics

Editions participated in:

December 2019